256 related articles for article (PubMed ID: 25519801)
1. Treatment options and outcomes of hospitalised tuberculosis patients: a nationwide study.
Yamana H; Matsui H; Fushimi K; Yasunaga H
Int J Tuberc Lung Dis; 2015 Jan; 19(1):120-6. PubMed ID: 25519801
[TBL] [Abstract][Full Text] [Related]
2. [Characteristics and treatment outcomes of INH-resistant or RFP-resistant tuberculosis].
Saito W; Nagayama N; Miyamoto M; Hara H; Suzuki J; Masuda K; Baba M; Tamura A; Nagai H; Akagawa S; Kawabe Y; Machida K; Kurashima A; Yotsumoto H
Kekkaku; 2003 Oct; 78(10):611-7. PubMed ID: 14621568
[TBL] [Abstract][Full Text] [Related]
3. Six- vs. eight-month anti-tuberculosis regimen for pulmonary tuberculosis under programme conditions.
Ukwaja KN; Oshi SN; Alobu I; Oshi DC
Int J Tuberc Lung Dis; 2015 Mar; 19(3):295-301, i-vii. PubMed ID: 25686137
[TBL] [Abstract][Full Text] [Related]
4. Treatment outcome of new culture positive pulmonary tuberculosis in Norway.
Farah MG; Tverdal A; Steen TW; Heldal E; Brantsaeter AB; Bjune G
BMC Public Health; 2005 Feb; 5():14. PubMed ID: 15698472
[TBL] [Abstract][Full Text] [Related]
5. Treatment of isoniazid-resistant tuberculosis with isoniazid, rifampin, ethambutol, and pyrazinamide for 6 months.
Nolan CM; Goldberg SV
Int J Tuberc Lung Dis; 2002 Nov; 6(11):952-8. PubMed ID: 12475140
[TBL] [Abstract][Full Text] [Related]
6. Factors influencing time to smear conversion in patients with smear-positive pulmonary tuberculosis.
Wang JY; Lee LN; Yu CJ; Chien YJ; Yang PC;
Respirology; 2009 Sep; 14(7):1012-9. PubMed ID: 19659516
[TBL] [Abstract][Full Text] [Related]
7. First- and second-line anti-tuberculosis drug resistance in Northwest Ethiopia.
Tessema B; Beer J; Emmrich F; Sack U; Rodloff AC
Int J Tuberc Lung Dis; 2012 Jun; 16(6):805-11. PubMed ID: 22390880
[TBL] [Abstract][Full Text] [Related]
8. Advanced stage of chronic kidney disease is risk of poor treatment outcome for smear-positive pulmonary tuberculosis.
Igari H; Imasawa T; Noguchi N; Nagayoshi M; Mizuno S; Ishikawa S; Kadomura M; Nishimura M; Yamagishi F
J Infect Chemother; 2015 Aug; 21(8):559-63. PubMed ID: 26048063
[TBL] [Abstract][Full Text] [Related]
9. Impact of country of origin on drug-resistant tuberculosis among foreign-born persons in British Columbia.
Moniruzzaman A; Elwood RK; Schulzer M; FitzGerald JM
Int J Tuberc Lung Dis; 2006 Aug; 10(8):844-50. PubMed ID: 16898367
[TBL] [Abstract][Full Text] [Related]
10. Results at 30 months of a randomised trial of two 8-month regimens for the treatment of tuberculosis.
Nunn AJ; Jindani A; Enarson DA;
Int J Tuberc Lung Dis; 2011 Jun; 15(6):741-5. PubMed ID: 21575292
[TBL] [Abstract][Full Text] [Related]
11. Pulmonary resection combined with isoniazid- and rifampin-based drug therapy for patients with multidrug-resistant and extensively drug-resistant tuberculosis.
Park SK; Kim JH; Kang H; Cho JS; Smego RA
Int J Infect Dis; 2009 Mar; 13(2):170-5. PubMed ID: 18768342
[TBL] [Abstract][Full Text] [Related]
12. The evolving epidemic of drug-resistant tuberculosis among children in Cape Town, South Africa.
Seddon JA; Hesseling AC; Marais BJ; Jordaan A; Victor T; Schaaf HS
Int J Tuberc Lung Dis; 2012 Jul; 16(7):928-33. PubMed ID: 22583610
[TBL] [Abstract][Full Text] [Related]
13. Surveillance of Mycobacterium tuberculosis drug resistance in Hong Kong, 1986-1999, after the implementation of directly observed treatment.
Kam KM; Yip CW
Int J Tuberc Lung Dis; 2001 Sep; 5(9):815-23. PubMed ID: 11573892
[TBL] [Abstract][Full Text] [Related]
14. Isoniazid- and streptomycin-resistant miliary tuberculosis complicated by intracranial tuberculoma in a Japanese infant.
Ishiwada N; Tokunaga O; Nagasawa K; Ichimoto K; Kinoshita K; Hishiki H; Kohno Y
Tohoku J Exp Med; 2013 Mar; 229(3):221-5. PubMed ID: 23470647
[TBL] [Abstract][Full Text] [Related]
15. Tuberculosis chemotherapy and sputum conversion among HIV-seropositive and HIV-seronegative patients in south-eastern Uganda.
Bwire R; Borgdorff MW; Sticht-Groh V; Rieder HL; Kawuma HJ; Bretzel G; Rüsch-Gerdes S
East Afr Med J; 1999 Jun; 76(6):307-13. PubMed ID: 10750516
[TBL] [Abstract][Full Text] [Related]
16. [Frequency of drug resistant tuberculosis in Poland in 2000 as compared to 1997].
Augustynowicz-Kopeć E; Zwolska Z; Jaworski A; Kostrzewa E; Klatt M; Swiderska A; Drozd I
Pneumonol Alergol Pol; 2002; 70(3-4):193-202. PubMed ID: 12271966
[TBL] [Abstract][Full Text] [Related]
17. Outcomes among tuberculosis patients with isoniazid resistance in Georgia, 2007-2009.
Gegia M; Cohen T; Kalandadze I; Vashakidze L; Furin J
Int J Tuberc Lung Dis; 2012 Jun; 16(6):812-6. PubMed ID: 22507372
[TBL] [Abstract][Full Text] [Related]
18. API TB Consensus Guidelines 2006: Management of pulmonary tuberculosis, extra-pulmonary tuberculosis and tuberculosis in special situations.
API Consensus Expert Committee
J Assoc Physicians India; 2006 Mar; 54():219-34. PubMed ID: 16800350
[TBL] [Abstract][Full Text] [Related]
19. Pattern of mycobacterial resistance to four anti-tuberculosis drugs in pulmonary tuberculosis patients in the state of Qatar after the implementation of DOTS and a limited expatriate screening programme.
Al-Marri MR
Int J Tuberc Lung Dis; 2001 Dec; 5(12):1116-21. PubMed ID: 11769769
[TBL] [Abstract][Full Text] [Related]
20. Tuberculosis treatment outcome and predictors in northern Ethiopian prisons: a five-year retrospective analysis.
Adane K; Spigt M; Dinant GJ
BMC Pulm Med; 2018 Feb; 18(1):37. PubMed ID: 29463234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
